> The EMEA has approved Bristol-Myers Squibb's Baraclude for hepatitis B. Report
> Crucell and DSM say they will set up a pharmaceutical research lab in the U.S. next year. The lab is expected to have about 50 staffers. Report
> Teva has stopped marketing a generic version of an Abbott antibiotic after Abbott sought a motion in federal court to halt sales. Report
> Replidyne has cut its IPO share price to $10. Report
> A British appeals court has upheld Pfizer's patent for a key ingredient to Lipitor. Report
> Oscient Pharmaceuticals announced that the FDA had agreed to review its application for Factive as a therapy for acute bacterial sinusitis. The agency had rejected Oscient's application in January. Report
> With its headquarters in California at capacity, Amgen is moving staffers to a facility in Colorado. Report
> CoTherix has gained exclusive rights in North America and Europe to Fasudil, a treatment for pulmonary arterial hypertension, from Asahi Kasei Pharma. Release
> Genelabs plans to raise $9 million through a stock sale. Report
And Finally… Much of Warren Buffett's fortune is likely to fund new research into the fight against malaria. Article